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ABSTRACT: Targeted hybridization enrichment prior to
next-generation sequencing is a widespread method for
characterizing sequence variation in a research setting,
and is being adopted by diagnostic laboratories. How-
ever, the number of variants identified can overwhelm
clinical laboratories with strict time constraints, the fi-
nal interpretation of likely pathogenicity being a par-
ticular bottleneck. To address this, we have developed
an approach in which, after automatic variant calling
on a standard unix pipeline, subsequent variant filtering
is performed interactively, using AgileExomeFilter and
AgilePindelFilter (http://dna.leeds.ac.uk/agile), tools de-
signed for clinical scientists with standard desktop com-
puters. To demonstrate the method’s diagnostic efficacy,
we tested 128 patients using (1) a targeted capture of
36 cancer-predisposing genes or (2) whole-exome cap-
ture for diagnosis of the genetically heterogeneous dis-
order primary ciliary dyskinesia (PCD). In the cancer
cohort, complete concordance with previous diagnostic
data was achieved across 793 variant genotypes. A high
yield (42%) was also achieved for exome-based PCD diag-
nosis, underscoring the scalability of our method. Simple
adjustments to the variant filtering parameters further al-
lowed the identification of a homozygous truncating mu-
tation in a presumptive new PCD gene, DNAH8. These
tools should allow diagnostic laboratories to expand their
testing portfolios flexibly, using a standard set of reagents
and techniques.
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Introduction
Next-generation sequencing (NGS) technologies have radically
transformed the approach to genetic testing, initially in academic
settings but increasingly also in clinical laboratories. The mas-
sive amount of sequence data generated by a single NGS instru-
ment can be harnessed to allow many permutations of concur-
rent testing of multiple genes in a number of patients. This allows
a reduction in costs and a simplification of testing through the
convergence of previously diverse laboratory methods. The asso-
ciated innovations in data analysis have permitted the emergence
of many new applications for NGS data [Shendure and Lieberman
Aiden, 2012]. Clinical diagnostic laboratories in particular have
been empowered to undertake increasingly ambitious sequencing
projects, resulting in a greater availability and range of diagnostic
tests.
The enrichment of the target DNA sequences prior to sequenc-
ing is a key step in most NGS methods, with the use of long-range
PCR (LR-PCR) being a popular choice for amplifying target regions
from a relatively small number of genes [Morgan et al., 2010]. With
this approach, currently available diagnostic gene panels often fo-
cus on major pathological targets such as BRCA1 (MIM #113705)
and BRCA2 (MIM #600185) for breast cancer or MLH1 (MIM
#120436), MSH2 (MIM #609309), and MSH6 (MIM #600678)
for hereditary nonpolyposis colorectal cancer [Morgan et al.,
2010].
If it is desired to screen a larger number of genes, the main choice
is between a highly parallel PCR-based approach and enrichment
by hybridization. Commercially available examples of the former
include the access array system (Fluidigm, San Francisco, CA) and
the RainDance micro-fluidics platform (RainDance Technologies,
Lexington, MA), whereas alternatives such as Haloplex and SureS-
elect (Agilent Technologies, Santa Clara, CA) employ enrichment
by hybridization. Using such reagents, diagnostic laboratories have
been able to sequence increasingly broad DNA targets in larger and
larger patient cohorts [O’Sullivan et al., 2012]. However, because
developing and validating bespoke capture reagents can be both
time-consuming and expensive, standard rather than customized
commercially available enrichment reagents have increasingly come
into use.
The diagnostic screening of multiple disease genes results in
the identification of unprecedented numbers of sequence vari-
ants. These variants must be both identified and interpreted for
likely pathogenicity before the preparation of clinical reports. If
done manually, this task can be both tedious and time-consuming,
resulting in significant human error. In common with many
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laboratories, we perform automated variant annotation using both
alamut-HT (Interactive Biosoftware, Rouen, France) to annotate
single-nucleotide changes or small indels and Pindel [Ye et al., 2009]
formore complex variants. These steps are ideally suited to automa-
tion on dedicated servers, and typically require only infrequent
configuration by an experienced bioinformatician. In contrast, the
assessment of individual annotated sequence variants for possible
pathogenicity requires a greater level of user input from a clinical
scientist, a process that cannot easily be automated, given our cur-
rent state of knowledge. This now constitutes the main bottleneck
in the reporting of pathogenic variants in NGS-based diagnostic
testing.
To address this issue, we have developed two programs, AgileEx-
omeFilter and AgilePindelFilter, which are specifically designed to
be used by clinical scientists on standard desktop computers. These
programs permit interactive screening of variants based on their ge-
nomic location and predicted effect on protein function, as well as
filtering against flexible genetic and quality criteria. To demonstrate
the utility of our hybrid diagnostic pipeline, we analyzed sequence
data from two patient cohorts. The first comprised 104 hereditary
cancer patients, whose DNA was enriched for target sequences us-
ing a custom-designed hybridization enrichment reagent capturing
the exonic regions of 36 cancer-associated genes (Supp. Table S1).
The second cohort consisted of 24 individuals with a family his-
tory of primary ciliary dyskinesia (PCD), who were analyzed using
whole-exome sequence data (Supp. Table S2).
Methods
Subjects
Subjects were recruited from the Yorkshire Regional Genetics Ser-
vice at the Leeds Teaching Hospitals NHS Trust. DNA was isolated
from peripheral blood leukocytes and stored in Tris–EDTA buffer
(pH 8.0) using a standard salting out protocol. Cohort 1 patients
(hereditary cancer) were divided into two subgroups. The first phase
of the analysis was performed on 57 individuals previously screened
by accredited clinical diagnostic laboratories for a subset of the genes
present on the 36-gene panel. Some of these patients were described
in our previous publication [Morgan et al., 2010]. Variant infor-
mation was available for these positive control samples, from their
corresponding clinical report. The second phase of analysis encom-
passed 47 patients prospectively recruited for extended hereditary
cancer testing; these patients were analyzed for differing subsets of
the 36-gene panel, depending on their individual family histories.
The cohort comprising 24 PCD family subjects was recruited for
targeted analysis of 18 already known PCD genes. Of these, 23 were
affected probands, and one was the mother of an affected child.
Exome-wide sequence variants were filtered according to the crite-
ria listed in Supp. Table S3. Initially, only variants located within
the 18 known PCD genes were further examined; however, if no
likely pathogenic variant was identified in this way, analysis was
extended to apparently autozygous regions [Carr et al., 2013]. Ad-
ditionally, for five of the PCD patients in whom amutation in the 18
known genes could not be found, a second sibling was available to
aid with autozygosity mapping (three unaffected and two affected
siblings).
Capture Array Design, Library Preparation, and Sequencing
A custom-targeted hybridization capture reagent for the di-
agnosis of hereditary cancer was designed using the eArray
system (https://earray.chem.agilent.com/earray/) (Agilent Tech-
nologies). Capture probes were targeted to the coding exons (in-
cluding 20 bp of flanking sequence) of 36 known cancer suscepti-
bility genes (Supp. Table S1). This comprised 591 coding exons and
a design target of 107,683 bp. A proportion of these genes offer rec-
ognized clinical utility and these were selected for investigation in
relevant patient referrals; the remaining genes were included for de-
velopment purposes. Samples from the PCD cohort were sequenced
following hybridization capture using theAgilentV5 exome reagent.
Genomic DNA (3 μg) was first sheared into 200–300 bp fragments
using a Covaris S2 (Covaris, Inc., Woburn, MA) and then purified
using a QiaQuick column (Qiagen, Chatsworth, CA). Illumina-
compatible sequencing libraries were prepared using Agilent library
preparation reagents as per the manufacturer’s instructions. A five-
cycle enrichment PCRwas used to generate the libraries, whichwere
captured using the relevant hybridization probe set. Either 16 or 10
cycles of posthybridization enrichmentPCRwere performed, for the
cancer gene capture reagent or the exome reagent, respectively. Dur-
ing the first phase of the hereditary cancer study, 10 indexed libraries
were pooled and sequenced on one lane of an Illumina HiSeq 2000
(Illumina, Inc., San Diego, CA). Following initial analysis, the num-
ber of pooled libraries was increased to 12 for the second phase.
Also, following the first phase of the hereditary cancer study, pro-
tocol recommendations were updated to enable PCR amplification
directly from the Dynabeads R© (Life Technologies Ltd., Paisley, UK).
Sequencing of the PCD cases was performed using both a HiSeq
2000 and HiSeq 2500 in high output and rapid modes, respectively
(see Supp. Table S4 for details). Four to six cases were pooled per
lane, depending on the run configuration. In all cases, paired-end
100-bp reads were generated.
High-Throughout Informatics Pipeline (Fig. 1A)
Raw data were converted to fastq.gz format and demul-
tiplexed using CASAVA v.1.8.2 (Illumina, Inc.). The per-
patient sequence data were aligned to the human reference
genome (hg19) using bwa v.0.6.2 [Li and Durbin, 2009].
Sam file processing and duplicate removal were performed us-
ing Picard v.1.85 (http://picard.sourceforge.net). GATKLite v.2.3-
4 was used to carry out indel realignment, base quality
score recalibration, variant discovery, and read depth anal-
ysis on the duplicate-removed coordinate-sorted bam files
[DePristo et al., 2011]. UnifiedGenotyper-created VCF files
were annotated with positional and functional information for
each variant using alamut-HT v.1.1.5 (http://www.interactive-
biosoftware.com/software/alamut/overview). Default parameters
were selected for all programs except the GATK UnifiedGenotyper.
For this tool, both SNPs and indels were identified concurrently
and the argument -minIndelFrac was adjusted to 0.15. A variant
pathogenicity score was appended to variants that had been previ-
ously identified by the Yorkshire Regional Genetics Service using a
curated variant list.
The alamut-HT output formed the basis of a variant report that
could be filtered using a range of parameters with AgileExomeFilter
(Fig. 1B; http://dna.leeds.ac.uk/agile). To archive the variant data
and calculate variant frequency information, VCF files outputted
by the UnifiedGenotyper were imported into a local instance of
LOVD3.0 [Fokkema et al., 2011]. Variant information was peri-
odically downloaded from this database, allowing the number of
observations of each point mutation to be appended to alamut-HT
reports as appropriate. All reported variants have been uploaded
to a LOVD database accessible at http://databases.lovd.nl/shared.
HUMANMUTATION, Vol. 35, No. 4, 434–441, 2014 435
Figure 1. Informatics pipeline for the analysis of targeted capture data. A: The high-throughput pipeline will typically be run centrally, with
dissemination of the processed data to diagnostic end-users (B) for further filtering and interpretation.
BWA-aligned bam files were screened using Pindel v.0.2.4t
to identify insertion/deletion variants [Ye et al., 2009].
Data output from Pindel was analyzed using AgilePindelFilter
(http://dna.leeds.ac.uk/agile). Manual inspection of the aligned
readswas performedusing the IntegrativeGenomicsViewer v.2.2.13
[Thorvaldsdo´ttir et al., 2013].
Concurrent Testing Using Locally Available
LR-PCR NGS Assays
The Yorkshire Regional DNALaboratory sequenced a proportion
of the 47 phase 2 hereditary cancer samples using their standard
LR-PCR NGS diagnostic assays. This included screening of 28 pa-
tients for BRCA1 and BRCA2; 24 for MLH1, MSH2, and MSH6;
20 for TP53; and 13 for APC andMUTYH. LR-PCR amplicons en-
compassed the coding regions and20bpofflanking sequenceof each
target gene. The LR-PCRNGSworkflow followedwas similar to that
described in Morgan et al. (2010), with improvements including li-
brary preparation on the Beckmann Coulter SPRIworks robot and
150-bp paired-end sequencing on an Illumina MiSeq. Variant anal-
ysis of samples tested via LR-PCR was performed using NextGENe
v.2.14 (http://www.softgenetics.com/NextGENe.html) (SoftGenet-
ics, PA).
Variant Confirmation
Variants identified via NGS and included on a clinical report
were confirmed by Sanger sequencing using an ABI3730 (Applied
Biosystems, Paisley, UK). Sequence chromatograms were scored
using Mutation Surveyor v.3.2 (http://www.softgenetics.com/
mutationSurveyor.html) (SoftGenetics).
SNP Analysis
In five PCDpedigrees forwhich no pathogenic variant was identi-
fied within the 18 known PCD genes, autozygous candidate regions
were identified.Genotypesof index cases andunaffected (threepedi-
grees) or affected (two pedigrees) siblings were determined using
the Affymetrix SNP 6.0 platform, and the data were analyzed using
AutoSNPa to identify regions of homozygosity concordant between
affected siblings [Carr et al., 2006].
Results
Sequencing and Alignment Metrics for Capture-Enriched
Sequencing Libraries
Sequencing was performed on an Illumina HiSeq in both high
output and rapid modes (run time of 11 days or ∼27 hr, respec-
tively). Rapid mode runs are ideally suited to clinical testing, since
fewer samples are required to initiate a sequencing batch and clus-
ter generation can be performed on-board the HiSeq instrument,
obviating the need to use a cBot. We obtained a remarkably even
per-sample readdistributionwithin eachpool of sequenced libraries
(Supp. Fig. S1). The range of percentages of total reads was 21.5%–
29.7% for a four-plex, 11.8%–19.5% for a six-plex, 8.6%–13.3% for
a 10-plex, and 6.0%–10.4% for a 12-plex. The number of pooled
hereditary cancer samples was increased from 10 to 12 per lane
(the maximum number of available indexes) following preliminary
coverage analysis of the first phase of samples. After sample demul-
tiplexing, the mean number of reads was therefore 41.8 million and
33.4 million for phase 1 and phase 2, respectively.
More than 99% of raw sequence reads were aligned to the hg19
reference sequence for all hereditary cancer samples. A large pro-
portion of these reads were flagged as PCR duplicates (Supp. Fig.
S2). The highest duplicate rate was identified in the phase 1 cancer
cohort (mean = 79.9%, range = 65.8%–91.2%). A number of process
improvements, notably performing an on-bead posthybridization
PCR, may have contributed to improving the PCR duplicate rate
for phase 2 (mean = 54.3%, range = 37.8%–69.9%). Nonetheless,
the small 36-gene capture region makes it inevitable that a signif-
icant proportion of reads identified as PCR duplicates are actually
genuinely coincident independent replicates, which are therefore
being discarded unnecessarily. Theoretically, therefore, the number
of samples that could be pooled per lane could thus be considerably
increased. Following duplicate removal, a mean of 8.2 million and
14.5 million aligned reads remained for phase 1 and phase 2 cancer
samples, respectively.
For exome analysis, the mean number of reads per patient was
114 million. As expected, the duplicate rate was considerably lower
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Table 1. A Summary of Known Deletion and Insertion Variants in the Phase 1 Hereditary Cancer Samples
Gene Transcript Variant Codon change I/D Number affected bases
BRCA1 NM 007294.3 c.2475del p.Asp825Glufs∗21 D 1
BRCA1 NM 007294.3 c.3005del p.Asn1002Thrfs∗22 D 1
BRCA1 NM 007294.3 c.4806del p.Gln1604Asnfs∗2 D 1
MLH1 NM 000249.3 c.207+1del D 1
MLH1 NM 000249.3 c.1489del p.Arg497Glyfs∗11 D 1
BRCA2 NM 000059.3 c.3545 3546del p.Phe1182∗ D 2
BRCA2 NM 000059.3 c.6275 6276del p.Leu2092Profs∗7 D 2
BRCA2 NM 000059.3 c.7673 7674del p.Glu2558Valfs∗7 D 2
MSH2 NM 000251.1 c.1226 1227del p.Gln409Argfs∗7 D 2
MLH1 NM 000249.3 c.1744 1746del p.Leu582del D 3
MSH2 NM 000251.1 c.1786 1788del p.Asn596del D 3
APC NM 001127510.2 c.1875 1878del p.Asn627Leufs∗2 D 4
BRCA2 NM 000059.3 c.6944 6947del p.Ile2315Lysfs∗12 D 4
FLCN NM 144997.5 c.890 893del p.Glu297Alafs∗25 D 4
MSH2 NM 000251.1 c.1457 1460del p.Asn486Thrfs∗10 D 4
PTEN NM 000314.4 c.956 959del p.Thr319Lysfs∗24 D 4
APC NM 001127510.2 c.3183 3187del p.Gln1062∗ D 5
MSH2 NM 000251.1 c.2502 2508del p.Asn835Leufs∗4 D 7
BRCA2 NM 000059.3 c.8736 8744del p.Asp2913 Ala2915del D 9
MLH1 NM 000249.3 c.197 207+20del p.Thr66Lysfs∗9 D 31
BRCA1 NM 007294.3 c.1175 1214del p.Leu392Glnfs∗5 D 40
FLCN NM 144997.5 c.347dup p.Leu117Alafs∗16 I 1
MSH6 NM 000179.2 c.4001+4 4001+8dup I 5
BRCA2 NM 000059.3 c.7762 7764delinsTT p.Ile2588Phefs∗60 D/I 3
I, insertion variant; D, deletion variant.
(11.1%), reflecting the much larger target size and consequent
paucity of truly coincident independent reads.
Coverage of Target Regions
Within the range of readnumbers generated in these experiments,
the number of reads mapping to target regions scaled linearly with
the total number of aligned, duplicate-removed reads (Supp. Fig.
S3), Thus, if the number of reads needed to achieve 100% variant
detection sensitivity using the informatics pipeline were defined, a
maximum number of samples that could be pooled per sequencing
lane could be derived. In practice, the number of available sequence
indexeswithwhich thepatients couldbe “barcoded”wouldprobably
impose limits.
Opinion varies concerning the read depth statistics required for
reliable variant calling. For diagnostic use, we currently aim for
50-fold coverage before accepting the genotype at a given genomic
position. By this standard, all positions in 587 of the 591 targeted
exons (plus 20 bp flanking sequence) could be genotyped in the
hereditary cancer cohort.Mean sequencing depth per base for phase
1 samples was 1,999, rising to 4,035 for phase 2 samples. For four
targets, coverage dropped below 50-fold, one within the ATM gene
and three within CDKN2A (Supp. Table S5). For the ATM exon
and one of the CDKN2A exons, this occurred in one patient only,
whereas the other two CDKN2A exons displayed reduced coverage
across multiple patients.
Approximately 90% of target regions in the 18 analyzed PCD
geneswere covered to a depth of at least 30 (Supp. Table S6). All PCD
patients in this study were consanguineous, and since homozygous
variants can be identified at lower read depths than heterozygous
ones, it might be acceptable to pool more patient samples in this
situation. Our present methodology succeeded in identifying the
heterozygous pathological variant in an unaffected carrier mother.
The reduced read depth of exome-based NGS will undoubtedly
reduce sensitivity of detection of some individual variants.However,
this is offset by a considerably lower cost than that of analyzing
18 genes by non-NGS methods. A corollary is that two goals of
diagnostic NGS sequencing should be the coherent reporting of
the regions for which low coverage was identified and defining the
mutation detection sensitivity in genes with known hot spots.
Performance of the Automated Pipeline
High-throughputmultistep computational pipelines for the anal-
ysis of genomic data have been employed for many years at large
genome centers. Their benefits include automationwith limiteduser
interaction and an ability to finely tune the analytical parameters to
each laboratory’s specific requirements. All individual components
of such pipelines must be known to work separately and in tandem
to ensure data preservation en route to the final output.We validated
our local pipeline running on a unix server with a large attached
storage array (Fig. 1A) by reanalysis of the phase 1 inherited cancer
cohort. An average of 82 variants across the 36 genes was identified
in each phase 1 patient. A subset of these was known from previous
diagnostic testing (depending on the nature of the original referral
request). The number of unique variants previously identified in
this cohort was 116, comprising 92 transition/transversion variants
and 24 indels. Of particular note was the ability of our NGS pipeline
to detect a 31-bp MLH1 deletion and a 40-bp BRCA1 deletion
(Table 1). One error in the LR-PCR was highlighted, due to a
deletion of MLH1 exons 16–19. This deletion removed a LR-PCR
primer binding site. The MLH1 variant (NM 000249.3) c.1668-
19A>G present on the nondeleted allele was consequently called as
homozygous in the LR-PCR assay. With capture enrichment, this
position was correctly scored heterozygous, since the nearby dele-
tion event did not interfere with the capture assay. Taking these data
into account, the total number of concordant genotypes across these
samples was 313. Capture NGS results were 100% concordant with
genotypes known from previous analysis.
Despite the apparently robust performance of this automated
pipeline, the resulting large variant datasets require interpretation
and downstream analysis from individuals with experience and
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Figure 2. The AgileExomeFilter user interface. Variants are displayed in rows, with the column headers outlining the annotation information for
each variant. The lower panel allows selection of filtering criteria such as zygosity status, variant location, and allele frequency. Boxed numbers
indicate the reduction in variant count following the selected filtering criteria (blue arrows), which lead to the identification of the pathogenic
homozygous LRRC6 mutation (NM_012472.3) c.630del (p.Trp210Cysfs∗12).
knowledge of the molecular basis for each disease tested. Although
the annotated data files exported by alamut-HT and Pindel can be
further analyzed by eyes, their size makes this laborious and error
prone. Consequently, we created two novel programs, AgileExome-
Filter and AgilePindelFilter (Fig. 1B) to assist with this.
Interactive Variant Filtering Using AgileExomeFilter
AgileExomeFilter allows the rapid sifting of variants annotated
by alamut-HT, with each variant that passes the active filters being
displayed as a single row in a grid (Fig. 2). (To ease visualization,
some alamut-HT data fields are combined or omitted.) To reduce
false positives, variants can be filtered on their VCF quality score
and their read depth. Remaining variants can then be screened us-
ing flexible user-specified criteria such as their location within a
set of specified genomic locations and/or within a set of specified
disease genes. If the mode of inheritance is known, variants can
be filtered by zygosity, for example, (1) genes with homozygous or
possibly compound heterozygous variants, for recessive disorders;
(2) homozygous variants only (recessive inheritance with parental
consanguinity); and (3) heterozygous variants only (dominant in-
heritance). Finally, variants can be filtered according to their likely
effect on gene product function. These parameters include selection
according to position within the gene (exon, intron, or splice sites),
possible effect on nearby splice sites, and possible effect of amino
acid changes on protein function.
This filtering is performed in real time, and so can be itera-
tively adjusted to observe multiple effects on the list of candidate
pathogenic variants. Conversely, to standardize the filtering of data
from patients with similar phenotypes, the filtering parameters
can be saved to file and reimported for subsequent analyses. (This
filtering parameter file can also be used to store a log of the filtering
procedure when used in a diagnostic setting.)
Indel Viewing and Filtering Using AgilePindelFilter
Because of the difficulties of identifying insertion/deletion vari-
ants within short-read NGS data, Pindel, a program specifically de-
signed to identify indels is included in our pipeline. Pindel analyzes
discordant read pairs, taking the unmapped read and performing
a computationally expensive split-read alignment using a genomic
search space predefined relative to the mapped read. The variants
identified by Pindel can be filtered by AgilePindelFilter in a similar
manner to the screening performed by AgileExomeFilter. Since Pin-
del exports variants in a number of different files, AgilePindelFilter
imports from a directory containing these files. Since the Pindel
variant data are more complex than that exported by alamut-HT,
the data are displayed one variant at a time, with most of the user
interface displaying the aligned reads relative to the reference se-
quence (Fig. 3). Within a gene, the variant’s position relative to the
exon/intron structure is shown below the alignment, along with a
text description of the variant.
Analysis can be restricted according to data quality, by imposing
a minimum number of supported reads. This cut-off is adjustable
according to the median read depth of the data and the diagnostic
purpose. For example, with the inherited cancer cohort, a value of
several hundred supporting readswas used, whereas the PCDexome
data were limited to tens of supporting reads.
Using our automated pipeline in combination with AgilePin-
delFilter, we successfully identified all 24 insertion/deletion vari-
ants that had been previously reported in the phase one cohort
(see Table 1). Although these variants were also identified using
the GATK variant caller’s UnifiedGenotyper function, the Pindel
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Figure 3. A: The AgilePindelFilter user interface. Reads are shown with respect to the reference sequence for a 510-bp BRCA1 exon 22 deletion.
The identified variants can be restricted to specific genes and their location within the gene. Quality parameters can be adjusted to display variants
that meet a required number of reads. B: The variant shown in panel A is visible in the IGV browser by the drop in coverage and the substantial
number of soft clipped reads. There is, however, no method by which the variant can be filtered out from the other sequence reads.
analysis provides a second independent method that can identify
insertion/deletion variants. It is recognized that searching for in-
dels using more than one algorithm may be necessary for optimum
sensitivity [Jiang et al., 2012]. Although scarce in the general popu-
lation, the “difficult” indels larger than 10 bp represent an important
group of disease-causing mutations.
Interestingly, Pindel detected the breakpoints of an exon 22
BRCA1 deletion at nucleotide resolution. This variant had been
previously detected using a multiplex ligation-dependent probe
amplification (MLPA) assay. This deletion was captured since one
breakpoint was located in the pull-down region. While reads con-
taining the deletion could not be aligned by BWA, their paired end
mates were mapped. This allowed Pindel to successful perform a
split-read alignment with the reads containing the deletion and so
identify this variant. This illustrates an important limitation on the
detection of very large deletions, as only those with at least one end
within a targeted region will be identified. Heterozygous deletions
of whole exon(s) whose breakpoints are not within a capture target
may still be missed unless quantitative read-count analyses prove
reliable enough to permit detection.
Clinical Validation of Hereditary Cancer Reagents
Following the successful identification of all known variants in
the phase 1 cohort, we prospectively analyzed 47 further patients
using the hereditary cancer panel. A mean of 84 variants per patient
was identified. Diagnostic testing of an average of seven genes per
patient had been requested, and for ethical reasons we restricted our
analyses to the requested genes. In this way, a mean of 13 variants in
five genes was identified per patient. To further maximize the vali-
dation potential of these samples, where possible, we concurrently
analyzed each using our standard LR-PCR assays. With the cap-
ture reagent, we correctly identified all 480 genotypes (101 unique
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Table 2. The Average Reduction in Variant Count for PCD Patients
After Filtering Using AgileExomeFilter
Filtering parameters Mean Range (n = 24)
Total variants 33,143 31,929–34,075
Retain if located in known PCD genes 94 68–119
Retain if exonic or splice sitea 66 49–80
Exclude if dbSNP minor allele frequency ≥0.10 15 7–21
Exclude if nonsynonymous variant 10 5–15
Retain if biallelic or homozygous 7 3–12
aSplice site is defined as 10 bp flanking the exon.
variants) identified by LR-PCR. Four false positive variant calls were
identified within the GATK-determined variant set. These included
two variants attributable to apparently misaligned reads and two
variants called due to the confirmed mutation being located in the
flanking sequence. No false positive insertion/deletion mutations
were identified in the coding regions (±2 bp flanking intron) when
concurrent analysis was performed with the LR-PCR data.
We report nine probably pathogenic variants (Supp. Table S7),
of which seven would have been detected by our routine LR-PCR
assay, whereas two were within genes not interrogated by the LR-
PCRmethod. In a patient with Peutz–Jegher syndrome, a heterozy-
gous STK11 variant (NM 000455.4) c.566C>T (p.Thr189Ile) was
identified as being probably pathogenic given previously published
functional work on this variant [Karuman et al., 2001]. A further
probably pathogenic heterozygous SMAD4 variant (NM 005359.5)
c.380G>T (p.Cys127Phe) was identified in a patient with multiple
stomach polyps and primary cholangiocarcinoma. This variant al-
ters a highly conserved residue in the MH1 DNA-binding domain.
In all cases, variants were confirmed by Sanger sequencing.
The total number of concordant genotypes that have been tested
by both the LR-PCR assay and hereditary cancer pull-down reagent
is 793, comprising 147 unique variants. Based on these validation
data,we consider thismethod tobe ready andappropriate for clinical
use.
Scalability of Our Approach: Targeted Exome Analysis
A logical extension to the use of targeted capture to enrich di-
agnostic targets is to perform the analysis of whole exomes. We
therefore applied our hybrid informatics pathway to the analysis of
24 subjects with PCD. Eighteen known genes were scrutinized in
these patients, yielding a mean of 94 variants per patient. Follow-
ing the filtering criteria outlined in Table 2 and Supp. Table S3, we
reduced the variant count to less than 15 in all cases. In nine out of
24 cases, we identified eight unique likely pathogenic variants. Of
these eight variants, four have been previously reported as a cause of
PCD. Subject 2010.1024 was the mother of an affected child and so
was heterozygous for the identified pathogenic variant. Six variants
were either nonsense or frameshift mutations, whereas the remain-
ing two were predicted to be pathogenic by in silico analysis (Supp.
Table S8).
The lack of causative mutations in the remaining 15 PCD sub-
jects might be attributable to overzealous variant filtering, but the
cancer cohort experience suggested that this was unlikely to be a
major factor. The lower coverage depth of the exome data might,
however, result in failure to call some variants. No new candidate
pathogenic variants were apparent when the filtering criteria were
relaxed. As mentioned above, a subset of indel mutations probably
remains undetectable without the addition ofmethods such as CNV
detection from read depth [Shi andMajewski, 2013] orMLPA.Most
likely, though, is that additional locus heterogeneity exists among
the PCD cohort. To test this, we performed a simple extension to
our initial 18-gene query, based on genetic criteria.
First Example of DNAH8Mutation in PCD
In five families where no pathogenic variants in known PCD
genes were identified, we performed SNP genotyping of the affected
proband and an affected or unaffected sibling. We then searched
the candidate autozygous regions in each family for homozygous
deleterious variants. In one patient, a homozygous nonsense variant
(NM 001371.2) c.1768C>T (p.Arg590∗) was revealed in DNAH8.
This gene encodes the ortholog of a known outer dynein arm heavy
chain component in Chlamydomonas and on that basis has been
suggested as a PCD candidate gene [Pazour et al., 2006]. However,
this represents the first report of amutation in this gene as a probable
cause of PCD. Both parents were carriers of this variant and none
of the three unaffected siblings were homozygous for the mutation.
Discussion
High-throughput targeted analysis of exome data has clear di-
agnostic applicability to current clinical practice. We have demon-
strated an unexpectedly high diagnostic rate of 42% for PCD, which
exhibits high genetic heterogeneity, with many genes remaining to
be identified. Particularly appealing for this type of diagnostic chal-
lenge is the fact that as new genes are identified, existing exome data
can be reanalyzed without the need for additional laboratory work.
A frequent criticism is that the coverage depth of the targeted
exome is significantly less than that obtainable by a smaller cus-
tom hybridization reagent, with consequent loss of sensitivity for
detection of some individual mutations. Our view is that these scru-
ples should not hinder diagnostic implementation: the increased
overall diagnostic yield that accrues from exome sequencing am-
ply justifies its use in any diagnostic setting in which the identity
of the disrupted gene is open to question. From the point of view
of laboratory workflow, the use of a uniform commercial reagent
offers clear advantages in terms of staff time and avoids the need for
revalidation of custom reagents.
Furthermore, as the cost of DNA sequencing continues to plum-
met, genetic testing strategies are likely to converge rapidly on one
common laboratory method. This will deliver whole-genome se-
quence at super high coverage, eliminating current technical limi-
tations. The remaining challenges will relate solely to data analysis
and interpretation, and it is at these levels that genetic testing will
need to adopt focused methods. The Agile software that we describe
here addresses a general need for clinical scientists to be able to
interrogate large variant datasets interactively, so as to make best
use of their professional skills to arrive at an ultimate diagnosis.
Ultimately, perhaps even this professional skill will be supplanted,
but there is no indication that this will come to pass until long
after whole-genome sequencing for diagnostic purposes becomes
ubiquitous.
The diagnostic value of exome sequencing for genetically hetero-
geneous disorders has been clearly shown here, with a diagnosis rate
of 42% on PCD cases. The same approach could easily be applied to
other groups of rare heterogeneous diseases. The workup required
to initiate such testing is minimal, involving only the scientifically
informed construction of new queries using AgileExomeFilter.
Although we have been using NGS for clinical diagnosis of in-
herited disease since 2010, wider adoption of NGS as a replacement
for PCR + Sanger sequencing has been slow. While some authors
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indicate that exome sequencing is not yet ready for the diagnos-
tic setting, we show here that given a correctly formulated clinical
question, even in genetically heterogeneous disorders high diagnos-
tic rates can be achieved [Sikkema-Raddatz et al., 2013]. Given the
ease with which AgileExomeFilter allows such queries to be con-
structed, concerns over per-variant false negative rates should not
stand in the way of affordable, clinically useful exome-based diag-
nosis, whereas in situations where very low false negative rates are
required, targeted capture reagents such as the one described here
for hereditary cancer provide noticeable advantages over PCR-based
methods.
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